The company is using the funding to develop its automated tissue sectioning device, SectionStar, in preparation for a launch into the non-clinical lab market, according to the release. Its eventual goal is to launch the device, which aids in the processing and interpretation of human and animal tissues, into the clinical lab market.
“… AI-driven algorithms for interpretation of human tissues — particularly cancer — when examined on a cellular level are vulnerable to the variability in the quality of those tissue cross-sections,” Clarapath CEO Eric Feinstein said. “Clarapath’s SectionStar consolidates many manual cutting, quality control and decision making steps into one piece of equipment, resulting in better quality tissue sections, faster processing efficiencies, and lower overall costs, all while providing richer data sets on those tissue specimens.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
